These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
162 related items for PubMed ID: 33273347
1. Dabigatran-induced esophageal injury: a case report. Zhang JR, Li CY, Li SN, Dong JZ, Ma CS. Chin Med J (Engl); 2020 Dec 05; 133(23):2897-2898. PubMed ID: 33273347 [No Abstract] [Full Text] [Related]
4. Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Lin S, Wang Y, Zhang L, Guan W. Drug Des Devel Ther; 2019 Feb 21; 13():1527-1533. PubMed ID: 31190734 [Abstract] [Full Text] [Related]
5. Very Late-Onset Dabigatran-Induced Esophageal Injury. Fujikawa K, Takasugi N, Goto T, Minatoguchi S. Can J Cardiol; 2017 Apr 21; 33(4):554.e15-554.e16. PubMed ID: 28343609 [Abstract] [Full Text] [Related]
7. Dabigatran-Induced Esophagitis Associated With Vomiting. Matsumoto Y, Senda E, Yamada H. Am J Gastroenterol; 2019 Apr 21; 114(4):548. PubMed ID: 30676363 [No Abstract] [Full Text] [Related]
8. Esophageal Injury Due to Long-term Use of Dabigatran. Maeda A, Fujikawa H, Wakabayashi T. Balkan Med J; 2022 May 24; 39(3):224-225. PubMed ID: 35332769 [No Abstract] [Full Text] [Related]
11. [Dabigatran specific antidote: new safety level in oral anticoagulation]. MMW Fortschr Med; 2015 Nov 05; 157(19):78-9. PubMed ID: 26953416 [No Abstract] [Full Text] [Related]
12. Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings. Darwiche W, Bejan-Angoulvant T, Dievart F, Babuty D, Angoulvant D, Fauchier L. Int J Cardiol; 2016 Mar 01; 206():89-92. PubMed ID: 26785030 [No Abstract] [Full Text] [Related]
13. [Severe dabigatran intoxication complicated by insufficient reversal by idarucizumab]. Hellfritzsch M, Hvas AM. Ugeskr Laeger; 2020 Apr 06; 182(15):. PubMed ID: 32286218 [Abstract] [Full Text] [Related]
14. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding. Quintard H, Viard D, Drici MD, Ruetsch C, Samama CM, Ichai C. Thromb Haemost; 2017 Jan 05; 117(1):196-197. PubMed ID: 27734073 [No Abstract] [Full Text] [Related]
15. Symptomatic exfoliative esophagitis induced by dabigatran. Cuadros Martínez M, Froilán Torres C, Gonzalo Bada N. Rev Esp Enferm Dig; 2018 Nov 05; 110(11):743-744. PubMed ID: 30238767 [Abstract] [Full Text] [Related]
19. Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review. Ohya Y, Makihara N, Wakisaka K, Morita T, Ago T, Kitazono T, Takaba H. J Stroke Cerebrovasc Dis; 2018 Jul 05; 27(7):e128-e131. PubMed ID: 29555397 [Abstract] [Full Text] [Related]
20. Dabigatran-Induced Spontaneous Hemopericardium and Cardiac Tamponade. Jelani QU, Gordon R, Schussheim A. Tex Heart Inst J; 2017 Oct 05; 44(5):370-372. PubMed ID: 29259514 [Abstract] [Full Text] [Related] Page: [Next] [New Search]